Barbeau Pharma, Inc., located in Evanston, Illinois, develops, gains marketing approval and markets or out-licenses specialty ethical pharmaceuticals. The company pursues the development and regulatory approval of drugs currently on the market which no longer enjoy patent protection and which are experiencing substantial off-label use for patient treatments. With several drugs under development, Barbeau identifies new opportunities for existing, off-patent therapeutics through a strategy of development for new indications that will also have the advantage of marketing protection provided by patents on the reformulated chemical entity or its method of manufacture, the Waxman-Hatch Act, or Orphan Drug regulations. The company focuses on unmet or under-served clinical needs in the areas of migraine prophylaxis, epilepsy and bipolar disorder, acute hypertensive crisis, chemotherapy induced nausea and vomiting, nocturnal incontinence and gastrotintestional disorders.
